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Abstract
Acute Rheumatic Fever (ARF) is a system-wide disease in which chronic, wide spread
inflammatory changes occur in response to a group A streptococcal (GAS) infection that most
often affects children and adolescents and those from developing countries. The aim of this study
is to calculate the global incidence of ARF and identify the frequencies of major and clinical
manifestations and risk factors globally to provide a better indication of the burden of disease
and additional information on the dispersion of manifestations and risk factors. A meta-analysis
was conducted by pooling cross-sectional and cohort studies, and Morbidity and Mortality
Weekly Reports (MMWRs) that were English, full-text, peer-reviewed articles published after
1990 that included ARF cases of any race or nationality that were aged 0 to 19 years at the time
of evaluation. Measures of interest included incidence rates and frequencies of clinical and major
manifestation of ARF. In total, 27 studies met all inclusion criteria; twelve (44.4%) were crosssectional and another 12 (44.4%) were cohort studies. A linear mixed effects model was used to
calculate a pooled risk ratio; however, heterogeneity was found to be significantly high across all
articles. When exploring heterogeneity of the effect by study region and age, those from the
Americas (β = -4.880, p <0.001) and Africa (β = -2.919, p = 0.021), and those that included
children under the age of 5 (β = -2.103, p = 0.006) had incidence estimates that were
significantly lower compared to their respective stratifications, indicating that characteristics of
these populations may be introducing bias. Clinical and major manifestations were unable to be
explored due to the way that these variables were presented. Although substantial heterogeneity
existed between studies, the results provide evidence of where gaps exist regarding ARF research
on a global scale. Properly describing the characteristics of this disease is the first step towards
creating adequate criteria and guidelines that will lead to better health outcomes for those
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suffering from ARF, reduce the economic burden of this disease, and improve the quality of life
of these individuals.
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Incidence, Clinical Manifestations and Risk Factors of Acute Rheumatic Fever: A Systematic
Review and Meta-Analysis of the Global Perspective
Chapter 1 Introduction
Acute Rheumatic Fever (ARF) is a system-wide disease in which chronic, wide spread
inflammatory changes occur in response to a group A streptococcal (GAS) infection (Chang,
2012). This disease most often affects children and adolescents (aged 3-19 years old), can also
affect adults and children younger than three years of age, (Carapetis, McDonald & Wilson,
2005; Chang, 2012). ARF occurs more frequently in developing countries and is considered a
rare event in most developed countries, except for Australia and New Zealand, due to its low
incidence rates by use of antibiotics (Azevedo, Pereira & Guilherme, 2012). Many of the signs
and symptoms of this disease are non-specific, so a wide range of differential diagnoses are
considered to reduce the underestimation of this disease (The Australian Guidelines, 2015). The
involvement of the heart, joints, skin, nervous system, and immune system are common among
individuals with this disease, with cardiac damage being of major concern (Chang, 2012). Each
year, 500,000 new ARF cases are seen world-wide, with an overall global incidence estimated
between 5 and 51 per 100,000 population (Tibazarwa, Volmink & Mayosi, 2008). About
280,000 of these new cases will then develop Rheumatic Heart Disease [RHD] and 233,000
individuals die to either ARF or RHD each year (Eroğlu, 2015).
Children who acquire a GAS infection and subsequently develop ARF, they are then at
risk for developing RHD, which is a prominent cause of morbidity and mortality in developing
countries, especially Africa and Asia (Kumar & Tandon, 2013; Steer, Carapetis, Nolan & Shann,
2002). RHD develops after long-term damage has occurred within the heart valves from
repeated manifestations of ARF (Baroux et al., 2013; Chang, 2012). RHD prevalence peaks in
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individuals aged 30 to 40 years and is responsible for numerous premature deaths (World Health
Organization [WHO], 2005). While the number of affected individuals has decreased in
developing countries, at least 15,600,000 individuals globally live with RHD (Eroğlu, 2015).
Studies suggest that, based on an annual 1.5% mortality rate, global deaths caused by RHD are
between 233,000 and 294,000 per year, but Asian countries, where it is more prevalent, showed
an annual 3.3% mortality rate accounting for 356,000 to 524,000 deaths per year (Carapetis,
Steer, Mulholland & Weber, 2005; Carapetis, 2008). This data suggests that the global mortality
rate may be higher than what has been previously proposed.
Definitions
Definitions for the introduction are listed here (Merriam-Webster, n.d.):
1

Pyogenic – marked by pus production

2

Collectin – soluble pattern recognition receptors

3

Laminin – a fibrous protein present in the basal lamina of the epithelia

4

GlcNAc – a monosaccharide/derivative of glucose; part of a biopolymer in the bacterial cell

wall
5

Toll like receptors – single, membrane-spanning, non-catalytic receptors usually expressed on

cells, such as macrophages and dendritic cells that recognize structurally conserved molecules
derived from microbes
6

Ficolins – a group of oligomeric lectins with subunits consisting of both collagen-like long thin

stretches and fibrinogen-like globular domains with lectin activity usually specific for Nacetylglucosamine (GlcNAc)
7

Lipoproteins – any of a group of soluble proteins that combine with, and transport fat, or other

lipids, in the blood plasma

11

8

Peptidoglycan – a substance that forms the cell walls of many bacteria, consisting of

glycosaminoglycan chains interlinked with short peptides
9

Lipotechioic acid – a surface-associated adhesion amphiphile from Gram-positive bacteria;

released from the bacterial cells after bacteriolysis
Complement – a group of proteins present in blood plasma and tissue fluid that combine with
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an antigen–antibody complex to bring about the lysis of foreign cells
Proinflammatory – a type of signaling molecule that promotes inflammation

11

Cytokines – any of a number of substances, such as interferon, interleukin, and growth factors,

12

that are secreted by certain cells of the immune system and cause inflammation
13

Immunocomplexes – complexes formed between an antigen and an antibody

14

Myosin – a fibrous protein that forms half of the contractile filaments of muscle cells; involved

in motion in other types of cells
15

Tropomyosin – a protein involved in muscle contraction; related to myosin and occurs together

with troponin in the thin filaments of muscle tissue
16

VCAM-1 – mediates both adhesion and signal transduction

17

Keratinocytes – an epidermal cell that produces keratin

18

Ligand – a molecule that binds to another molecule

Protein factor H – a complement control protein; regulate the Alternative Pathway of the

19

complement system; ensures that the complement system is directed towards pathogens or other
dangerous material and does not damage host tissue
20

Fibrinogen – a soluble protein present in blood plasma, from which fibrin is produced

21

Monoclonal antibodies – an antibody produced by a single clone of cells or cell line; consists of

identical antibody molecules
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22

Vimentin – a major intermediate filament with roles in cell adhesion, migration, and signaling

23

Human leukocyte antigen – helps the immune system distinguish the body's own proteins from

proteins made by foreign invaders, such as viruses and bacteria
Superantigens – a class of antigens that cause non-specific activation of T-cells resulting in

24

polyclonal T cell activation and massive cytokine release
25

Accessory cells – any of various cells of the immune system that interact with T cells in the

initiation of the immune response
Jurkat cells – an immortalized line of human T lymphocyte cells that are used to study acute T

26

cell leukemia, T cell signaling, and the expression of various chemokine receptors susceptible to
viral entry
27

Tumor Necrosis Factor (TNF)-α – a major pro-inflammatory cytokine involved in early

inflammatory events; triggers a series of various inflammatory molecules

13

Chapter 2 Literature Review
Streptococcus pyogenes and ARF
Streptococcus pyogenes (GAS) is a Gram-positive extracellular bacterial pathogen that
colonizes the throat or skin (Cunningham, 2000). These bacteria produce a variety of pyogenic1
infections involving the mucous membranes, tonsils, skin and deeper tissues, which in turn cause
diseases such as pharyngitis, impetigo, necrotizing fasciitis, and scarlet fever (Cunningham,
2000). GAS also plays a significant role in the development of post-streptococcal infection
sequelae, such as ARF, acute glomerulonephritis, and reactive arthritis. Of these, ARF and RHD
have been shown to be the most serious autoimmune sequelae caused by a GAS infection
(Cunningham, 2000). ARF results from the production of autoreactive antibodies and T cells that
cross-react with components of the GAS and host tissues, specifically in the heart (Cunningham,
2000).
Pathogenesis of S. pyogenes in ARF
The pathophysiological model of this disease begins with a pharynx infection caused by
S. pyogenes. This bacterium bears epitopes that are similar to the structures of cardiac and
skeletal muscles (molecular mimicry), which means they are cross-reactive, or recognize both
human and bacterial epitopes (Azevedo et al., 2012). This cross-reactivity is initially fought by
the innate immune system, which employs the mannose-binding lectin (MBL) pathway
(Azevedo, et al., 2012). MBL is an innate pattern-recognition collectin2, an acute phase protein,
that binds to N-acetylglucosamine4 (GlcNAc) (or surface sugar) in the streptococci cell wall,
which is similar in structure with the laminin3 in the heart (Reason, Schafranski, Jensenius &
Steffensen, 2006; Ramasawmy et al., 2008; Schafranski et al., 2008). Toll-like receptors5 (TLRs)
and ficolins6 (FCNs) in innate immunity also play a role in mediating inflammatory reactions
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against GAS infections. TLRs have the responsibility to mediate inflammatory reactions against
a wide variety of pathogens by binding to bacterial sites that are broadly shared by pathogens
(Azevedo et al., 2012). It has been previously reported that TLR-2 interacts with the
lipoproteins7, peptidoglycan8 and lipotechoic acid9 structures found on the surface of S.
pyogenes, which then initiates an immune response (Berdeli et al., 2005). On the other hand,
FCNs are pattern-recognizing proteins that bind to bacterial cells, which then activates the innate
immune response by either binding to collectin cellular receptors or initiating the complement10
lectin pathway (Azevedo et al., 2012).
The innate immune system, which was triggered when the bacterial cells stimulated
various immune system components, then activates the immune components of the adaptive
immune system, causing the body to increase the production of proinflammatory11 cytokine12
and antibodies. Cytokines that are often involved in inflammation include interleukin-1 (IL-1),
IL-6, and TNF-α (Azevedo et al., 2012). The over production of cytokines via this reaction then
furthers the inflammatory process and expands the lymphocytes. For example, rheumatoid
arthritis manifests in the joints due to antibodies precipitating into immunocomplexes13 and
activating complement, which causes inflammation to occur (Azevedo et al., 2012).
Autoimmunity is then triggered via molecular mimicry, producing autoantibodies that target both
bacterial and human cells. Autoantibodies act against cardiac structures, mainly myosin14,
laminin, and tropomyosin15, by promoting the adhesion molecule vascular cell adhesion protein 1
(VCAM-116) to recruit monocytes and macrophages that are also proinflammatory in nature.
(Azevedo et al., 2012).
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Colonization
For infection to take place, S. pyogenes must adhere and colonize the skin or the throat.
Colonization is described in the literature as a weak interaction with the mucosa at first, followed
by a second adherence event that confers specific tissue specificity and high-avidity adherence
(Hasty, Ofek, Courtney & Doyle, 1992). The initial reaction is potentially between lipoteichoic
acid (LTA) and the host cells, since it can recognize a wide range of molecules, and the second
adhesion event is dependent on which proteins are involved. Schrager et al. (1998) found that the
role of the M protein, a major virulence factor for ARF, in the second step of adhesion is
dependent on the serotype and host cell source. M protein types 6 and 24 were shown to adhere
to keratinocytes17 in skin cells, but not type 18 M protein. The authors hypothesized that these
proteins expressed a ligand18 that attaches to external skin keratinocytes, but not ones taken from
the oropharynx (Schrager et al., 1998). Environmental factors expressed in the respective areas
of the body may also be important cues for which adhesion molecules need to be expressed for
survival (Cunningham, 2000). This provides evidence that GAS which invade the skin are
different than those that cause pharyngitis.
Virulence Factors of S. pyogenes
M protein
The major virulence factor that determines how disease progresses after a GAS infection
is the M protein. Eighty M proteins have been identified, and there exists over 180 different M
serotypes defined by M protein gene (emm) typing (Chang, 2012; Cunningham, 2012). The M
protein is directly involved in the pathogenesis of S. pyogenes with different M serotypes
translating into different degrees of virulence (Chang, 2012). This protein is located on the
surface of the cell wall and cell membrane of the bacteria, and binds to complement regulatory
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protein factor H19 and fibrinogen20 (Chang, 2012). Binding to protein factor H activates the
bacteria’s antiphagocytic properties, but binding to fibrinogen activates the complement/contact
pathways, depending on how severe the infection is (Chang, 2012). Activating the immune
system produces cytokines, which are responsible for the wide-spread inflammation that is
associated with ARF.
Through investigating outbreaks of ARF, 16 M proteins have been shown to be
associated with the disease: M1, M3, M5, M6, M11, M12, M14, M17, M18, M19, M24, M27,
M29, M30, M32 and M41 (Cunningham, 2000). Of these, Type M1 and M3 are the most
commonly associated with rheumatic fever (Cunningham, 2000). In 1989, it was shown that
there were two distinct classes of streptococcal M proteins; serotypes that were often associated
with ARF shared a surface exposed antigenic domain that was localized on the C repeat block of
the M6 protein (Bessen & Fischetti, 1989). The repeat in this conserved antigenic domain is said
to be present in M proteins that cause ARF and is missing in strains with M proteins that do not
cause ARF, providing further evidence that these two groups have different virulence properties
(Bessen & Fischetti, 1989). In addition, there are certain emm types that are more rheumatogenic
than others (Stollerman, 1991). Analyzing strains of bacteria during outbreaks in the United
States showed that the most common emm subtypes associated with ARF were M types 1, 3, 5,
6, and 18 (Smoot et al., 2004). To further support this, studies have shown that M serotypes 2,
49, 35, 40, 60, and 61 are associated with pyoderma and glomerulonephritis while serotypes 1, 3,
5, 6, 14, 18, and 19 and 24 are associated with pharyngitis and rheumatic fever (Bisno, 1995a;
Bisno, 1995b; Stollerman, 1997;).
The M protein is a strong virulence factor because this protein has a high rate of
molecular mimicry. This protein has an alpha-helical heptad with a repeating structure that
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resembles human proteins like tropomyosin, vimentin, laminin and keratin (Cunningham et al.,
1992; Cunningham et al., 1993; Fenderson, Fischetti & Cunningham, 1989; Manjula & Fischetti,
1986). Though exact pathogenesis has not been determined, it appears that the cytotoxic
antibodies recognize epitopes on the surface of heart cells, and once they interact they cause
damage (Gulizia, Cunningham & McManus, 1991; Gulizia, Cunningham & McManus, 1993). In
2000, a study conducted by Galvin and colleagues showed that anti-GlcNAc/anti-myosin
monoclonal antibody21 (mAb) 3.B6 from rheumatic carditis patients were cytotoxic to human
endothelial cell lines and reacted with human valvular endothelium and its underlying basement
membrane (Galvin, Hemrick, Ward & Cunningham, 2000). The other important feature of this
mAb is that it also reacts with the protein laminin, which may explain its reactivity with the
valve surface. The authors determined that this data supports the hypothesis that cross-reactivity
in carditis association with ARF causes injury at the endothelium and the underlying matrix of
the valve (Galvin et al., 2000). The T-cell response to M proteins has also been investigated
regarding its role in the immune response to S. pyogenes in ARF patients, with evidence
suggesting that cytotoxic T-cells are stimulated by M proteins, which causes the T-cells to attack
and damage the heart (Dale & Beachey, 1987; Hutto & Ayoub, 1980).
Molecular Mimicry
Molecular mimicry between GAS and host antigens is the main mechanism for the
development of manifestations of ARF (Galvin, Hemric, Ward & Cunningham, 2000). This
phenomenon is the sharing of epitopes between different antigens, in this case between GAS and
the host (Cunningham, 2000). The main protein that has been researched regarding its crossreactivity with cardiac muscle is the M protein. When the crystallized GAS M1 protein was
evaluated, it showed how the alpha helical coiled-coil structure and epitopes of the protein are
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recognized in alpha helical proteins by host cells, causing cross-reactivity between GAS and
cardiac myosin (McNamara et al., 2008). The authors found that mutations in the M1 protein,
which produces the alpha helix shape, stabilized the shape and diminished the virulent
proinflammatory and cardiac myosin cross-reactive properties of the M1 protein, which is
opposite of what is normally expected. However, it must be emphasized that what allows the
function of the M protein to bind to the cross-reactive sites and the subsequent inadvertent
production of antibodies is the irregularities that are found in the M protein structure.
Autoantibodies
The presence of autoantibodies against the heart have shown to be associated with ARF
since 1945 (Cavelti, 1945). Then in 1964, antibody and complement complexes were reported to
be deposited in the hearts of patients with RHD (Kaplan, Bolande, Rakita & Blair, 1964). These
anti-heart antibodies persisted in patients with rheumatic reoccurrences but did decline after the
initial episode. When it was demonstrated that anti-heart antibodies could be absorbed from
human sera by GAS or their cell walls or membranes, it was the first indication that these
antibodies reacted with GAS (Kaplan, 1963; Kaplan & Suchy, 1964; Kaplan & Svec, 1964;
Zabriskie & Freimer, 1966). Sera from these patients reacted with heart and skeletal muscle
(Zabriskie, 1967). With the use of mAbs, it was discovered that myosin was the autoantigen in
the heart and streptococcal cross-reactive antigens were present in both the cell walls and the
membranes of the bacterium (Barnett & Cunningham, 1990; Barnett, Ferretti & Cunningham,
1992). In addition, these same mAbs have been shown to also recognize streptococcal M protein
(Dale & Beachey, 1985; Dale & Beachey, 1986; Dale & Beachey, 1987). Antibodies that react
towards the GlcNAc in the cell walls of streptococci display cross-reactivity against laminin,
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cardiac myosin, and vimentin22, which results in the phenomenon of molecular mimicry
(Cunningham, 2000).
Human Leukocyte Antigen mechanisms
Though the mechanism for the association of human leukocyte antigens23 (HLAs) and
ARF is unknown, there are two theories that exist as to what the relationship may be (Bryant et
al., 2009). One theory postulates that similarities exist between the GAS antigens causing ARF
and the HLA molecules. Support for this theory was found when investigators discovered that
anti-streptococcal serum caused significantly increased toxicity to B lymphocytes with HLADR4 containing cells compared with DR4 negative lymphocytes (Rajapakse et al., 1990). They
suggested that what led to the defective B-cell antigen presentation was the strong antigenic
similarity between HLA-DR4 and the streptococcal antigen. The defect in the antigen
presentation then leads to aberrant cytokine production and antibody formation against proteins
on heart valves, myocardium, brain, and joint tissue (Galvin, Hemric, Ward & Cunningham,
2000). However, this pathway exists in both ARF patients and the controls, which does not
accurately describe the progression of the disease in some individuals. The second theory is that
structural similarities cause GAS antigens to mimic HLA molecules, which in turn initiates an
over abundant immune response (Kil, Cunningham & Barnett, 1994). MHC class II antigens,
like HLA, has a structure that contains both an alpha and a beta chain (Paul, Schwartz, & Datta,
1989). Kil, Cunningham and Barnett (1994) showed that the beta chain of HLA was similar to
the 67-kDa streptococcal protein they used as their GAS antigen. In addition, they found that all
the ARF serum tested reacted strongly with the antigen. This suggests that there is crossreactivity between this antigen and MHC class II molecules.
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More recently, another theory has been suggested. After binding to the antigenic peptide,
the HLA complexes involved may initiate an inappropriate T-cell activation (Fae et al., 2005).
This model posits that the HLA complex on the surface of the antigen presenting cell presents
the streptococcal peptide to peripheral T-cells that have escaped immune tolerance. The peptides
recognize and then activate the T-cells (Fae et al., 2005). They then cross-react with similar selfantigens that are unable to identify as self, which then initiates an immune response. The same
study provided further evidence for this theory, describing an immunodominant peptide in the
M5 protein that was bound to HLA-DR53 (Fae et al., 2005). This protein was recognized by an
infiltrating T-cell clone, suggesting that the peptide presents itself to cells.
It is important to note the gap in years since these theories have been published and the
year that this information is presented in this article. The mechanisms that have been described
previously are all viable theories as to the pathogenesis of ARF, however, nothing has been ruled
out or studied further to the author’s knowledge. However, it should be emphasized that in vivo
research should be conducted to determine the real-time processing of the M protein molecule
during active infection (Wang et al., 1993). This would help establish a consensus as to which of
these theories, or if all of them, accurately describe the pathogenesis of S. pyogenes during an
ARF attack.
Superantigen24
In 1990, it was still thought that since the effects of the M protein on large populations of
T cells did not parallel classical T cell epitope activation like conventional antigens, that this
protein could possibly be a superantigen (White et al., 1989). To test this, one study evaluated
the possible superantigenic properties by using Pep M5 to stimulate highly purified human
peripheral T cells with or without the presence of accessory cells25 (ACs) (Tomai et al., 1990).
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They found that although MHC class II molecules were required for the presentation of the
antigen, there was no MHC restriction evident. After binding to MHC class II molecules, M5
stimulates T cells bearing Vβ 8 sequences (e.g. Jurkat cells26), which is a location that is known
to bind with other superantigens, indicating that M5 is a superantigen (Fleischer, Schrezenmeier
& Conradt, 1989; Kappler et al., 1989; Tomai et al., 1990). To date, it has been determined that
pep M5 is a superantigen to human T cells bearing Vβ2, Vβ3, and Vβ8 elements (Tomai et al.,
1991). Another study conducted by Kotb and colleagues (1990) showed that if the M5 protein
was immobilized or cross-linked, it had the ability to stimulate Jurkat cells, but not normally
purified human T cells, to produce the cytokine IL-2.
Risk Factors
Though there is limited research on the risk factors, there are three elements that are
thought to be responsible for ARF and RHD: host genetic susceptibility, virulence factors of
Streptococcus pyogenes and environmental factors such as poverty, household overcrowding,
low educational attainment, poor nutrition, and reduced access to medical care (Baroux et al.,
2013; Steer et al., 2002). Studies have shown that incidence rates of ARF are not only higher in
developing countries but are also higher among minority populations in higher income countries,
such as Aboriginal communities in Australian’s Northern Territory, the Hamilton and Maori
populations in New Zealand, and Samoa populations in the South Pacific (Steer et al., 2002).
However, it is unclear if the differences between ethnic groups are attributed to streptococcal
exposure, clinical and major manifestations of ARF, treatment of infection, or genetic
susceptibility (Carapetis & Currie, 1996; Carapetis, Currie, & Matthews, 2000).
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Genetic Susceptibility
Just as not all GAS strains are capable of causing ARF, not everyone is susceptible to
contracting ARF (The Australian Guidelines, 2015). Research suggests that approximately 3-5%
of individuals in any population have an inherent susceptibility to ARF, but the cause of this is
unknown (Carapetis, Currie, & Matthews, 2000). Before diagnostic criteria had even been
revised, family studies suggested that ARF could be familial, but the unknown genetic factor was
thought to be autosomal recessive and had limited penetrance (Wilson, Schweitzer & Lubschez,
1943). A few decades later, twin studies showed that both twins did not usually develop ARF
and lower than expected concordance indicated that it is not a simple mendelian single-gene
inheritance (Taranta et al., 1959). The fact that both twins did not usually develop ARF also
provides evidence that an environmental factor plays a role in the susceptibility of this disease. If
it had solely been genetic, then both twins would get ARF. However, a meta-analysis in 2011
looked at twin pairs to estimate the heritability of ARF and found that the pooled proband-wise
concordance risk for ARF was 44% in monozygotic twins and 12% in dizygotic twins (Engel et
al., 2011). These results showed that the risk of ARF in a monozygotic twin with a history of
ARF, the co-twin has an increased risk of ARF by more than 6 times compared to that of
dizygotic twins. With the heritability estimate at 60%, there is evidence that shows the
importance of genetic factors in ARF (Engel et al., 2011).
It is unlikely that a single gene is responsible for how the host responds to the
pathogenesis of GAS (Bryant et al., 2009). ARF potentially involves different bacterial antigenic
triggers, differences in humoral and cellular immune responses, and differences in what areas of
the body are damaged. Although strong associations exist between susceptibility and disease,
genetically susceptible individuals do not invariably develop ARF after exposure to rheumatic
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strains of GAS (Kuttner & Krumwiede, 1941). During their investigation of 3 outbreaks of ARF
with different types of S. pyogenes at a sanitarium, Kuttner & Krumweide (1941) found that the
incidence of recurrences varied greatly. The first outbreak had a recurrence rate of 50%, the
second had no recurrences recorded, and the third had a very small amount of recurrence occur.
However, no differences were found between the effective and non-effective strains when they
were compared (Kuttner & Krumwiede, 1941). This could reveal that certain combinations of
genes and environmental factors are needed for the progression of a pharyngeal infection to
ARF.
Immune System
Genetic susceptibility to ARF is no surprise considering autoimmune and rheumatic type
diseases are often associated with susceptibility related to expression of a particular MHC
antigen phenotype (Cunningham, 2000). Major histocompatibility antigens and potential tissuespecific antigens are under investigation to show if there are potential risk determinants
associated with ARF (Cunningham, 2000). Different HLA class II antigens have been found to
be associated with ARF and no associations have been found between HLA class I antigens
(Ayoub et al., 1986; Azevedo et al., 2012). No single HLA haplotype or combination exists that
is consistently associated with susceptibility (Bryant et al., 2009). Also, some studies have found
that only particular clinical features of ARF are associated with HLA. For example, one study
found a significant association between HLA-A10 and HLC-DR11 in individuals with carditis,
but not with those without carditis, who had higher frequencies of HLA-C2 (Ölmez et al., 1993).
However, the association may manifest, differences exist between these antigens and ethnic
groups.
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The HLA-D7 is the most frequent HLA to be associated with ARF among populations
(Guilherme & Kalil, 2010). As research in this field has expanded, more HLAs have been shown
to be associated with ARF. There is a higher frequency of HLA-DR4 in Caucasian patients with
ARF and higher frequencies of HLA-DR2 in African American populations with ARF (Ayoub,
Barrett, Maclaren & Krischer, 1986). In another study, South African populations with ARF
were shown to have higher rates of HLA-DR1 and HLA-DRw6 (Maharaj et al., 1987). In
Brazilian populations, it was shown that individuals with ARF have an increased frequency of
HLA-DR7 and HLA-DRw53 (Guilherme et al., 1995). Conflicting associations of HLA
phenotypes and ARF between ethnic groups provides evidence that MHC associations in ARF
are more complex than originally believed (Cunningham, 2000). This also provides evidence that
different strains are responsible for the development of ARF in different countries (Azevedo et
al., 2012).
A non-HLA B-cell marker used to identify ARF patients has also been studied, providing
100% accuracy in diagnosing ARF in the United States (Khanna et al., 1989; Patarroyo et al.,
1979). This marker is known as D8/17 or 883 and is so accurate because Mab D8/17 reacts with
33 to 40% of B cells from patients with a history of ARF compared to only 5 to 7% in patients
without a history of ARF (Khanna et al., 1989). The highest percentage of positive cells were
found in probands with ARF (33.5%), with unaffected siblings having 2.96% and parents having
3.86% positive cells. These results are consistent with an autosomal recessive mode of
inheritance, which is consistent with previous research. Another study that looked at this same
marker in an Aboriginal Australian population showed similar results (Harrington et al., 2006).
The mean proportion of D8/17-positive B cells was 39.3% in previous ARF cases, 22.5% in first
degree relatives, and 83.7% in patients with current ARF.
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However, this B cell marker does not seem to be this robust in all populations. Though
the percentage of positive cells was higher among all ethnic groups, one study found that only
66% of North Indians with ARF were found to test positive for D8/17 cells (Kaur et al., 1998).
The authors developed a new Mab called PGI/MNII to test as a potentially more accurate B-cell
marker on North Indians with ARF. This Mab reacted with samples from 86% of North Indians
with ARF, suggesting that there may be differences in B-cell markers between ethnic groups. To
further explore this association in the North Indian population, Kumar, Kaul, Grover and
Ganguly (2000) found that the antibodies PG-12A, PG-13A, and PG-20A were found in higher
amounts compared to controls. There were approximately 90% rheumatic fever patients positive
with these monoclonal antibodies compared to only 4% of controls. This suggests that stratifying
by ethnic group is required when using markers to identify individuals who have had or currently
have ARF.
Gene Polymorphisms. There have been several studies that examine the role of
polymorphisms in the promoter region of Tumor Necrosis Factor-α27 (TNF-α). It has been shown
that associations exist between RHD and Mexican individuals, both in allele (TNF-α-308A and 238G) and genotype (Hernandez-Pacheco et al., 2003). Another association was found with
valve damage, but the specific valve affected showed no association. Further supporting
evidence was found in Brazilian ARF individuals who also had an increased number of TNF-α308A polymorphisms (Ramasawmy et al., 2007). However, an Egyptian study found that this
was only true in individuals that were homozygous for the TNF-α-308A gene (Settin, AbdelHady, El-Baz & Saber, 2007). The authors also found evidence of a higher number of the TNFα-238 gene, but it was the A allele, not the G allele. On the other hand, a Turkish study found no
association between TNF-α polymorphisms and ARF (Settin et al., 2007).
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Few other gene polymorphisms have been studied in association with ARF. One study
found an association between immunoglobulin Fcγ-RIIA polymorphisms and susceptibility to
ARF (Berdeli, Celik, Ozyurek & Aydin, 2004). They suggested that a possible mechanism for
this association was that this polymorphism caused an inability of the immune system to remove
immune complexes that ultimately cause the damage associated with this disease. Another study
evaluated the association between T-cell polymorphisms and the development of RHD. The
authors found no associations between polymorphisms in T-cell α- and β-chains and RHD when
looking at Maori and Caucasian populations (Abbott et al., 1995). Toll-like receptor (TLR)
polymorphisms have only recently been studied, but it has been shown that TLR-2 receptor has a
strong association with ARF in children (Berdeli et al., 2005).
The contradictory results in both cases discussed previously indicate that it is still unclear
if these polymorphisms are related to ARF susceptibility. In addition, other polymorphisms may
exist that have not been studied to date. On the other hand, these results could also suggest that
just the presence of a genetic polymorphism alone is not enough for an individual to develop
ARF. It may be that genetic polymorphisms in TNF-α or Fcγ-RIIA must be paired with other
genetic susceptibilities, such as HLA, or with various environmental factors that are thought to
be associated with ARF.
Gender
Gender has not always been considered a risk factor for ARF because most evidence
suggests that this disease occurs equally between males and females (Karaaslan, Oran, Reisli &
Erkul, 2000; Olgunturk, Canter, Tunaoglu & Kula, 2006; Örün et al., 2012). However, research
has shown conflicting evidence for this. Some studies have shown that males have up to a 1.4
times higher risk of contracting ARF compared to females (Breda et al., 2012; Quarshi, 2009). In
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addition, another study found that a similar risk for males, and this association remained after
stratifying by ethnicity (RR: 0.80, 95% CI: 0.70-0.93; Gurney, 2015). However, the authors did
not hypothesize as to why this association occurred. In contrast, female preponderance for ARF
has been suggested in Australian populations (Hanna & Clark, 2010).
Environmental Factors
ARF was once considered a disease of temperate climates, but is now more common in
tropical areas and developing countries since it was rarely seen elsewhere (Steeg, Walsh &
Glickstein, 2000). With few exceptions, most racial or ethnic differences in incidence are
attributed to low socioeconomic status (SES), poor housing, and overcrowding (Quarashi, 2009).
SES has been the longest assumed environmental influence on ARF (Steer, Carapetis, Nolan &
Shann, 2002). In two large Northern Territory Aboriginal communities where ARF is endemic,
extreme levels of overcrowding was found. The median number of individuals per house was 17
and 14 and a median number of individuals per bedroom of 6.9 and 7.5, respectively (Brown et
al., 2007; McDonald et al., 2006). In a small town in the Democratic Republic of Congo,
children living in households with more than 8 individuals had an increased risk of RHD
(Longo-Mbenza et al., 1998). However, evidence for the association between overcrowding and
ARF is not always consistent. In Serbia, overcrowding has not been found to be associated with
ARF (Adanja, Vlajinac & Jarebinski, 1988). This suggests that overcrowding and its relationship
to ARF are more complex in how populations contract ARF and how the disease progresses, or
may act as a confounder since it can occur in both rural and urban areas.
Rurality has also been suggested to be a risk factor for ARF, but the evidence is
conflicting. Urban areas have been thought to be a risk factor for ARF because of overcrowding,
and often these places have poor sanitation and hygiene practices (Chagani & Aziz, 2002; Steeg,
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Walsh & Glickstein, 2000). Gurney et al. (2015) found that rurality had a somewhat protective
effect; those that lived in rural areas were nearly half as likely to sustain ARF compared to those
living in urban areas. However, a study conducted in India has shown that there is a rural
predilection in diagnosed ARF cases, which was accompanied by high amounts of overcrowding
and all cases came from a low SES status (Ramu & Shankar, 2015). Indigenous Australian
populations are known for having the highest incidence rate, and they often live in remote or
rural areas (Noonan et al., 2013). This provides evidence that there must be set environmental
conditions and host susceptibility, taken into geographical context, might be what causes ARF to
manifest.
Access to medical services is a risk factors to those who live in rural areas or those who
have low SES and may not have health insurance. Poverty leads to delayed access to medical
care, which means children are not receiving the appropriate care and timely antibiotics (Chagani
& Aziz, 2002). In addition, living in remote or rural areas also increases the likelihood that
health services are not able to be used. Smith et al. (2011) stated that their evidence supported
the claim that delayed presentation to a hospital by children in rural and remote areas is a
significant cause of delayed treatment and an increased risk for more severe symptoms of ARF.
In addition, the authors showed that it is almost guaranteed that if the individual lives in an area
where there is access to medical care (i.e. urban areas) that they will have an early diagnosis.
Overall, it is unlikely that there is only one environmental factor that puts an individual at
a higher risk of developing ARF, but rather an association, or an interaction, of many factors. For
example, living in a remote or rural region may mean that there is limited access to health care,
that the family has an issue with overcrowding and poor housing conditions, and have a low
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SES. If a household contains these risk factors, or only certain ones, it can cause variations in the
risk across populations.
Diagnostic Criteria
The diagnostic criteria for ARF was originally created by Dr. T. Duckett Jones in 1944 to
remedy the over diagnosis of ARF in the United States and has remained the benchmark for
diagnosis for the past 70 years (Hajar, 2016; Seckeler & Hoke, 2011). These criteria are based on
signs and symptoms that are often associated with this disease and are known as major and minor
manifestations. Major and minor manifestations were separated into different categories, which
was based on the diagnostic importance of a finding (Dajani et al., 1992). If there is evidence of
a preceding GAS infection via a rapid strep test, the presence of two major manifestations or one
major and two minor manifestations indicate a high probability that the individual has ARF
(AHA, 1992). If there is no evidence of a preceding infection, then ARF is considered to be
unlikely in that individual. Major manifestations consist of carditis, arthritis, subcutaneous
nodules (SN), erythema marginatum (EM), and chorea. Minor manifestations include fever,
arthralgia, elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels,
and prolonged PR interval on an electrocardiogram. The PR interval is the onset of the P wave in
an echocardiogram to the start of the QRS complex, and when this is prolonged (i.e. greater than
200 ms) it is indicative of a first-degree heart block (Cheng et al., 2009). This blockage causes
damage to the heart, which is a hallmark of ARF.
In 1992, an update to the Jones Criteria established the initial attack in ARF, expanded on
the available tools for diagnosis and clarified the available antibody testing for detecting GAS
infections (American Heart Association [AHA], 1992). However, when applying these
guidelines, the diagnosis is often missed in some populations (Hajar, 2016). In addition, since
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these criteria were first developed, our knowledge of the global epidemiology and its variable
presentation have changed. Due to the dangers of the sequalae, modifications have been made by
the American Heart Association in 2015 to take current epidemiology and evidence supporting
echocardiography in the diagnosis of carditis, instead of electrocardiography (Gewitz et al.,
2015). Even though there have been updates to increase the sensitivity of the criteria, diagnosis
has proven to be difficult, especially in regions where incidence is high (Eroğlu, 2015).
Before 2015, the diagnosis of ARF was most commonly conducted using the 1992
modified Jones Criteria that consists of major and minor manifestations that occur when this
disease is acquired (Eroğlu, 2015). When this update was released, there was still no single
symptom, sign, or laboratory test that could be used to diagnose ARF, and this is still true today
(AHA, 1992; Kumar & Tandon, 2013). In addition, this update was only designed to establish
the diagnosis in those who have an initial attack and was not designed to include individuals who
had previously had the disease and have a recurrent attack (AHA, 1992).
Even though more individuals were better able to be diagnosed when these guidelines
were introduced, there are three circumstances in which ARF diagnosis does not entirely fit
(AHA, 1992). Chorea, and in some cases insolent carditis, may be the only manifestation that
occurs in an individual who has ARF. In both these cases, individuals often seek medical
attention months after initial onset of disease, thus presenting with insufficient evidence to fulfill
the criteria (AHA, 1992). The third circumstance is when an individual has a recurrent attack
(e.g. a new episode in an individual with a previous history), because these cases can be less
apparent. A key example is that evidence of carditis is difficult to establish in these individuals
unless a different valve is affected in the recurrent compared to the initial attack, or pericarditis is
present (AHA, 1992). Thus, diagnosis must be made with caution when using these criteria.
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In 2006, the National Heart Foundation of Australia (NHFA) and the Cardiac Society of
Australia and New Zealand (CSANZ) drafted guidelines for the diagnosis and management of
ARF and RHD (Carapetis, Brown, Wilson & Edwards, 2007). Revisions included the
development of high and low risk groups and the addition of subclinical carditis (SCC),
polyarthralgia, and aseptic mono-arthritis as major manifestations. The new diagnostic criteria
created for high and low risk groups was based on evidence suggesting that ARF is observed
more commonly among Australia and New Zealand’s native and indigenous populations
(Carapetis et al., 2007). Thus, high risk groups include individuals living in communities with an
incidence of ARF of more than 30 per 100,000 per year in those aged 5 to 14 years, and low risk
groups include all other groups in the population. Differentiation between initial and recurrent
episodes of ARF was also established in this update. For both high and low risk groups, the
diagnosis of ARF includes 2 major OR 1 major and 2 minor manifestations, PLUS evidence of a
preceding GAS infection (Carapetis et al., 2007). The diagnosis of recurrent attacks of ARF was
also the same for both high and risk groups, with an individual needing 2 major OR 1 major and
2 minor manifestations OR 3 minor manifestations, PLUS evidence of a preceding streptococcal
infection.
Even though the diagnosis of ARF is the same between these groups, the major and
minor manifestations used to diagnose individuals varies between high and low risk groups.
Evidence of polyarthralgia or aseptic mono-arthritis is included as a minor manifestation for
individuals in low-risk groups, but it is considered a major manifestation for individuals in high
risk groups (Carapetis et al., 2007). The diagnosis of carditis in ARF patients in high risk groups
must include subclinical evidence of rheumatic valvular disease on an echocardiogram, or
subclinical carditis, but is not needed when diagnosing carditis in low risk groups. Even with
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these changes, under diagnosis of ARF, especially in Australia, was still a primary concern
(Carapetis et al., 2007).
The next major update was developed by the NFHA in 2015. Among the most important
changes made to the document was a new definition for Probable ARF, a definition change to
recurrent episodes of ARF, and expansions on the sections for echocardiography and subclinical
carditis (The Australian Guidelines, 2015). In addition, there were several major changes made
to the diagnosis of ARF in definite cases, including: (1) the ability to diagnose recurrent cases of
ARF that occur in high-risk groups with only one major PLUS one minor manifestation, (2) the
inclusion of mono-arthralgia as a minor manifestation in high-risk individuals, (3) classifying
fever as a minor manifestation based on the availability of reliable history of the use antiinflammatory medication in the individual (The Australian Guidelines, 2015). Adding
echocardiography to the criteria did not mean that it was mandated, since endemic countries
often cannot afford this technology. Ideally, these countries need access to echocardiography, but
it costs 40 times as much as an electrocardiogram. This may be easier for countries like
Australia, where they have a national healthcare program that covers 75% of general
practitioners, 85% of specialists and 100% of public in-hospital costs, but not for countries where
healthcare is not universal (Australian Institute of Health and Welfare (AIHW), 2012). These
changes make the Jones Criteria less restrictive in its diagnosis towards certain high-risk groups
that may have atypical or delayed presentations, such as the Indigenous population in Australia
and New Zealand.
The importance of these changes can be seen when exploring the literature focused on
indigenous populations. One study looking at Australia’s Northern Territory found that 31% of
individuals with suspected ARF had a range of presentations that did not fit the Jones Criteria
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(Ralph et al., 2006). The authors suggested the creation of probable and possible cases of ARF to
capture this group and to provide them with the correct dose of antibiotics for treatment, which
was taken into consideration in this revision. A probable ARF can be either highly-suspect or
uncertain, can happen in an initial or a recurrent attack, and is defined as an individual whose
clinical presentations fall short by either one major or one minor manifestation or does not have a
positive serology result, but ARF is the most likely diagnosis (The Australian Guidelines, 2015).
Delayed presentation and incomplete investigation of clinical testing can also cause cases to fall
within this group of individuals.
After the Australian Guidelines had been published, the American Heart Association
created another update to the Jones Criteria. The addition of high and low risk population groups
to the Australian Guideline directly influenced the creation of the low-risk and moderate- to
high-risk populations in this update (Gewitz et al., 2015). Any populations with an ARF
incidence of ≤ 2/100,000 in school age children and RHD prevalence of ≤ 1/1,000 at all ages
were defined as low-risk populations and all others were defined as high-risk populations
(Eroğlu, 2015). This update also included initial and recurrent attacks and possible cases of ARF,
with the same definitions and manifestations as those used in the Australian Guidelines (Gewitz
et al., 2015).
Purpose of Current Study
The aim of this meta-analysis is to first calculate the global incidence of ARF and
identify the frequencies of major and clinical manifestations and risk factors globally. The
second aim of this study is to further explore incidence, major and clinical manifestations and
risk factors by looking at differences between populations. Robustness of the study will also be
explored by comparing data between diagnostic methods. This can provide a better indication of
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the burden of disease and provide additional information on the dispersion of manifestations and
risk factors to offer insight towards possible revisions to the Jones Criteria that can result in
increased sensitivity in classifying ARF cases compared to other updates.
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Chapter 3 Methods
The review protocol has been registered in the systematic review registry on PROSPERO
in January 2018 (registry CRD42018080673).
Criteria for considering this meta-analysis
Studies
For articles to be included, they had to have contained calculations of incidence of ARF.
Articles could also have information pertaining to the frequencies of risk factors and clinical and
major manifestations of ARF. Studies had to be written in English, be published after 1990, and
the populations evaluated had to have been done so after 1990.
Participants
To be included in the review, participants in the studies had to have been assessed or
evaluated for the study using the Jones Criteria 1992 update, the associated ICD 9/10 code, the
2015 Jones Criteria update (Dajani et al., 1992; Eroğlu, 2016) or any variation of the Australian
Guidelines for the diagnosis of ARF (Carapetis et al., 2007; Eroğlu, 2016). The ICD 9 & 10 are
the hospital billing codes associated with ARF that directly correspond to the 1992 Jones Criteria
Revision (Eroğlu, 2016). These codes included: 390-398 from the ICD-9 and ICD I0.0-I09.9
from the ICD-10 (Aato-Carr et al., 2008; Beaudoin et al., 2015; Milne et al., 2012; Smith et al.,
2011). The age range of all the participants were between 0 and 19 years of age, and were from
any ethnicity or nationality.
Types of Outcome Data
Results of the included studies contained estimates for the following quantitative data:
incidence, risk factors, clinical manifestations, major manifestations or any combination of these
variables.
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Primary Outcomes
The primary outcomes for this meta-analysis included estimates for incidence of ARF
and frequencies of clinical and major manifestations within varying populations. Incidence was
calculated using incidence rates. Clinical manifestations, or minor criteria, included are
polyarthralgia, joint pain, fever, ESR and prolonged PR on an ECG. Major manifestations, or
major criteria, included are carditis, arthritis, chorea, erythema marginatum, and subcutaneous
nodules. Carditis measurements include mitral and aortic regurgitation, mitral and aortic stenosis,
tricuspid regurgitation, and any combination of these measurements.
Secondary Outcomes
The secondary outcomes for this meta-analysis include risk factors for ARF. Risk factors
included in the analyses are: socioeconomic status, ethnicity, gender deprivation status, and
house crowding, and rurality.
Search methods for identification of studies
Manual and electronic searches were performed to collect all relevant studies, which was
completed in December 2017. Only full-text peer-reviewed articles were included in the metaanalysis. All articles included in the searches and meta-analysis were published between 1990
and 2017, and are in English.
Electronic searches
Over 300 electronic databases, including PubMed, PNAS, and JSTOR were searched
using the Grand Valley State University (GVSU) Library website, which is backed by Summon.
The University Libraries at GVSU purposefully collect, teach, display, discover, disseminate and
preserve information, in all its forms, connecting scholars and learners to resources (Grand
Valley State University Library [GVSU], 2017). We additionally searched the Centers for
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Disease Control and Prevention (CDC) archive for Morbidity and Mortality Weekly [MMWR]
reports that included information on Acute Rheumatic Fever. Full text of articles or MMWR that
could not be obtained using the GVSU library or CDC archives were obtained via Google
Scholar search.
Filters used while searching for journal articles included: date rage of 1990 to 2017,
journal articles, and full-text only while on the GVSU Library website. The search words that
were used in Keyword searches on the GVSU Library website include: Rheumatic fever +
Causes, Incidence of Rheumatic Fever, Prevalence of Rheumatic Fever, and Acute Rheumatic
Fever MMWR. No keywords were used while searching for articles on Google Scholar, only the
title of the article or the citation was used to search for specific papers that were unavailable
through the GVSU library.
Manual Searches
The references list from all selected eligible studies from the electronic searches was used
to find additional sources. The articles searched manually were then analyzed using the inclusion
criteria listed above to determine if the articles could be included in the study.
Selection of studies
Studies included in the meta-analysis include cross-sectional, cohort studies and
MMWRs. Cohort studies could be either retrospective or prospective observational studies.
Data extraction and management
Data extracted from the studies include estimates for incidence of ARF and frequencies
and percentages from risk factors, major manifestations and minor manifestations. Data
management was done in Microsoft Excel. Data analysis was performed in R version 3.4.3.
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Assessment of risk of bias in included studies
Each paper included in the meta-analyses was assessed for risk of bias by a single
reviewer using the NewCastle-Ottawa Quality Assessment Scale (NCOS; Wellis et al., 2014).
Quality assessment was determined the tool’s criteria that include the following elements:
selection, comparability, and exposure. Each element has a list of criteria within them that should
be present for the study to be considered minimally biased (Wellis et al., 2014). To do this, a
“star” system is employed that marks whether the criteria is present within the study in question.
Within the selection and exposure elements, one star can be awarded to each of the following
items: case definition, representativeness of cases, selection of controls, definition of controls,
ascertainment of exposure, same method of ascertainment for cases and controls, and nonresponse rate. Within the comparability element, two stars can be awarded to the following
criteria: comparability of cases and controls and ascertainment of exposure based on the design
or analysis. Each article can obtain a maximum of 9 stars through this system. The higher the star
ratings in each category, the less likely bias will influence the study. A minimum score of 5 was
required for the study to be considered for inclusion in the analyses, resulting in the exclusion of
two articles.
Measures of incidence
Incidence was calculated using incidence rates provided from the studies when
population denominator data was reported, or abstracted and calculated based on number of
cases reported by the authors and populations at risk from government census websites. A linear
mixed-effects model was used to calculate the pooled risk ratio for the incidence of ARF and
95% confidence intervals for all eligible studies. Linear mixed-effect models incorporate both
ﬁxed and random-effects terms in a linear predictor expression from which the conditional mean
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of the response can be evaluated (Bates et al., 2014). Since this meta-analysis attempts to explore
many covariates and the data points are not truly independent since they represent a group of
individuals and not individuals separately, the linear mixed effects model seemed to be
appropriate to use. This is because this model allows for analysis to be completed even when
highly structured data has a low sample size and there are many covariates to explore (Hajduk,
2017). This method is also beneficial in cases where data points are not truly independent from
one another, since the model does take this into account when pooling data.
Measures of risk factors, clinical and major manifestations
Clinical and major manifestations were abstracted and summarized using frequencies and
presented in tables.
Data synthesis, assessment and investigation of heterogeneity
Heterogeneity refers to any kind of variation across studies, whether it is between
patients, interventions, outcomes definitions or study design, which is important to consider
when pooling data (Blend, n.d.; Ryan, 2016). Clinical and methodological heterogeneity, which
refer to differences among participants and in data collection methods, respectively, was taken
into consideration when synthesizing data (Ryan, 2016). Heterogeneity across studies was
evaluated using the Cochrane Q χ2 test set at a significance threshold of 10%, and the τ2 and I2
statistics were calculated to quantify the proportion of variance due to heterogeneity (Ryan,
2016). The same test was used when evaluating moderators, and is denoted QM. If the χ2 value is
greater than the degrees of freedom, has a low p-value and a high I2 statistic, this indicates
heterogeneity across the studies. The ‘meta’ package in R was used to determine heterogeneity
using the ‘metarate’ function and the ‘metafor’ package in R was used to test for heterogeneity
using the meta-regression function.
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Sensitivity analyses
A series of sensitivity analyses were conducted to explore the robustness of the results.
Meta-regression was used to examine the impact of moderator variables on the effect size of the
studies and assessed the appropriateness of comparing studies based on heterogeneity. When
significant heterogeneity exists, the information was not pooled. Additionally, due to a number
of papers without exact population denominator values, these papers were excluded and the main
analyses were replicated to account for papers in which exact population denominators could not
be determined.
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Chapter 4 Results
After searching through three of the search word combinations, our literature search
identified 50 journal articles and MMWRs through electronic searches. Once manual references
were found, 241 studies were searched and evaluated for inclusion (Figure 1).
Rheumatic fever +
causes
n = 16,488

Incidence of Rheumatic
Fever
n = 10,765

Prevalence of
Rheumatic Fever
n = 9,009

Acute Rheumatic
Fever MMWR
n =5

n=
Article in question must
be relevant to the study
n = 24

Article in question must
be relevant to the study
n = 20
n=4

Article in question must
be relevant to the study
n=3
n=4

MMWR must have
information on ARF & be
published after 1990
n=3

All references of these papers were read through and ones with relevant titles (i.e. acute
rheumatic fever prevalence, incidence, causes, or risk factors were selected and manually
searched for.
n = 241

Papers must have the inclusion criteria present.
n = 52

Papers must have the following criteria: presence of appropriate
outcome measures.
n = 26

Papers must be able to be grouped
into appropriate geographical
locations
n = 26

Papers must have received 5 - 9
stars on the NewCastle Ottawa
Quality Scale
n = 26

Population
denominators were
available
n = 24

Total Number of
papers eligible for
inclusion in study
n = 27

Figure 1. Article Search Flow Chart. This figure illustrates the steps taken to retrieve all
relevant articles to include in the meta-analysis.
Of these, 52 articles contained the elements of the inclusion criteria. Those that included the
outcome measures of interest (26) were then evaluated using the NCOS quality assessment score.
All articles scored a 5 or higher, which meant they were all appropriate to include. Population
denominators were unable to be calculated for two of the 26 articles due to lack of census data
availability. In total, 27 studies met all inclusion criteria. Twelve (44.4%) were cross-sectional
and another 12 (44.4%) were cohort studies. The median NCOS score was 6 (range 5 to 9).
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NCOS scores were not required for the MMWRs since they did not contain any other
information other than incidence rates, and are not considered cross-sectional nor cohort studies.
The World Health Organization’s (WHO) Study regions were used to describe the
geographical distribution of studies selected for inclusion: 3 from the Americas, 7 from the
Western Pacific and European regions, 6 from South-East Asia, 2 from Africa and the Eastern
Mediterranean Regions (WHO, n.d.). Nineteen (70.4%) of the studies included children under
the age of 5. Study populations were evaluated in the 1990s (22.2%), 2000s (44.4%), or spanned
both decades (33.3%). The most common diagnostic criteria used for the diagnosis of ARF was
the 1992 Jones Criteria (77.8%), followed by the ICD 9 & 10 (18.5%), and the 2012 Australian
Guidelines (3.7%). Characteristics of the studies can be found in Table 1.
Table 1
Characteristics of Included Studies
Article

Study Years

WHOSR

Study Design

Cases

NewCastle
Ottawa Scale

Noonan et al.
Smith et al.
Beaudoin et al.
Corsenac et al.
Steer et al.
Milne et al.
Atato-Carr et al.
Bavdekar
Ramu et al. (a)
Ramu et al. (b)
Routray
Zaman et al.
Ahmed et al.
Vinker et al.
Grassi et al.
Breda et al.
Kocevar et al.
Qurashi
Cilliers
Gapu et al.
Roodpeyma et al.

2007-2010
2000-2008
2011-2012
2012-2013
2005-2007
1993-2009
1998-2004
1995
2004-2006
2004-2006
1991-2000
2005
1991
2000-2005
1992-2006
2000-2009
2008-2014
1994-2004
1993-2010
2012-2013
1992-2002

Western Pacific
Western Pacific
Western Pacific
Western Pacific
Western Pacific
Western Pacific
Western Pacific
Southeast Asia
Southeast Asia
Southeast Asia
Southeast Asia
Southeast Asia
Southeast Asia
European
European
European
European
Eastern Mediterranean
African
African
Eastern Mediterranean

Cross-sectional
Cohort
MMWR
Cross-sectional
Cross-sectional
Cross-sectional
Cohort
Cohort
Cross-sectional
Cross-sectional
Cohort
Cross-sectional
Cross-sectional
Cross-sectional
Cohort
Cohort
Cohort
Cohort
Cohort
Cross-sectional
Cohort

151
26
65
38
24
1007
68
86
36
36
1330
36
7
40
135
88
19
83
207
16
102

7
5
5
5
7
6
5
7
6
6
5
5
5
6
7
5
5
5
6
6
6
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Karademir et al.
Karaaslan et al.
Narin et al.
Tunks et al.
Koo et al. (a)
Koo et al. (b)

1990-1992
1993-1998
1998-2011
1998-2008
1993
1994

European
European
European
Americas
Americas
Americas

Cross-sectional
Cohort
Cohort
Cross-sectional
MMWR
MMWR

228
274
624
59
69
54

Overall incidence rates from all 27 studies were pooled to determine the amount of
heterogeneity found between studies (Figure 2).

Figure 2. Overall Incidence Rates of ARF among included studies.
Due to high heterogeneity in the overall model, the cause of the heterogeneity was
explored in separate models by stratifying by: WHO study region, inclusion of children under the
age of 5 in the study, decade the study was conducted in, and diagnostic criteria used (Appendix
1). Heterogeneity was found to be high among all stratifications (Table 2).
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6
7
6
5
-

Table 2
Heterogeneity in the Overall Incidence Rates of Acute Rheumatic Fever

Stratification

I2
(%)

Overall
100
WHO Study Region
Americas
100
Western Pacific
100
South-East Asia
99
European
100
African
83
Eastern Mediterranean
99
Age 5
< Age 5
100
≥ Age 5
100
Decade
1990
100
2000s
99
Spans both
100
Diagnostic Criteria
1992 Jones Criteria
100
ICD 9/10
100
2012 Australian Guidelines
N/A
Note. I2 values of 100% were rounded.

τ2

p-value

3.451

<0.001

4.842
4.364
1.802
1.256
0.163
1.066

<0.001
<0.001
<0.001
<0.001
0.02
<0.001

2.585
3.186

<0.001
<0.001

5.069
3.566
2.310

<0.001
<0.001
<0.001

2.455
2.564
N/A

<0.001
<0.001
N/A

For example, in the instance of WHO study region, the I2 statistic was broken down for
each region, ranging from 83 to 100%. This percentage represents the amount of heterogeneity
between the articles in each region, and indicates how much heterogeneity is being introduced
into the analysis.
Significant heterogeneity was observed via meta-regression within all strata (Table 3).
The mixed effects model for WHO study region and children under the age of 5 years for overall
incidence were both statistically significant, indicating that part of the heterogeneity in the true
effects are related to some of these two predictors (QM = 22.148, df = 5, p = 0.0005; QM =
7.631, df = 1, p = 0.006, respectively).
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Table 3
Meta-regression in the Overall Incidence Rates of Acute Rheumatic Fever
Stratification

QM

WHO Study Region
22.148
Americas
Western Pacific
South-East Asia
European
African
Eastern Mediterranean
Age 5
7.631
< Age 5
≥ Age 5
Decade
5.598
1990
2000s
Spans both
Diagnostic Criteria
2.998
1992 Jones Criteria
ICD 9/10
2012 Australian Guidelines
Note. I2 values of 100% were rounded.

β

I2
(%)
99.62

-4.880
REF
-1.277
-1.467
-2.917
-1.301
99.79
-2.103
REF
99.82
REF
2.073
2.075
99.81
REF
1.795
-0.666

p-value
0.0005
<0.001
REF
0.144
0.080
0.021
0.300
0.006
0.006
REF
0.061
REF
0.029
0.037
0.223
REF
0.096
0.742

When exploring heterogeneity of the effect by study region and age, those from the
Americas and Africa, and those that included children under the age of 5 had incidence estimates
that were significantly different from their respective stratifications, indicating that
characteristics of these populations may be introducing bias into the present study (Figure 3;
Figure 4). The estimated average risk ratio is significantly lower for the Americans and Africa
compared to the West Pacific (β = -4.880, p <0.001; β = -2.919, p = 0.021, respectively). The
estimated average risk ratio was also significantly lower for studies that included children under
the age of 5 compared to those that did not (β = -2.103, p = 0.006).
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Figure 3. Overall Incidence Rates of Acute Rheumatic Fever in included studies stratified by
WHO Study Region.
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Figure 4. Overall Incidence Rates of Acute Rheumatic Fever stratified by inclusion of
children under or over the age of 5 for included studies.
The mixed effect model for overall incidence by decade (1990s vs. 2000s) revealed a
suggestive trend towards heterogeneity being related to the decade in which the study was
conducted but did not meet the threshold for statistical significance (QM = 5.598, df = 2, p =
0.061). The estimated average risk ratio was higher for studies that evaluated incidence rates of
ARF spanning both the 1990s and 2000s compared to studies exclusively evaluating ARF
incidence rates in the 1990s (β = 2.075, p = 0.037). The estimated average risk ratio was also
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statistically higher for studies that only evaluated incidence rates of ARF in the 2000s, compared
to those that were exclusively studied in the 1990s (β = 2.073, p = 0.029).
Incidence rates for males and females from 19 articles were pooled to determine
heterogeneity (Figure 5; Figure 6).

Figure 5. Female Incidence Rates of Acute Rheumatic Fever among included studies.
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Figure 6. Male Incidence Rates of Acute Rhematic Fever among included studies.
Using the same stratifications as before, heterogeneity was assessed, with high I2 values
being present for all variables (Appendix 2; Table 4; Table 5).
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Table 4
Heterogeneity in the Female Incidence Rates of Acute Rheumatic Fever
Stratification

I2
(%)
99

Overall
WHO Study Region
Americas
N/A
Western Pacific
99
South-East Asia
98
European
99
African
80
Eastern Mediterranean
99
Age 5
< Age 5
99
≥ Age 5
99
Decade
1990
100
2000s
98
Spans both
99
Diagnostic Criteria
1992 Jones Criteria
99
ICD 9/10
99
2012 Australian Guidelines
N/A
Note. I2 values of 100% were rounded.

τ2

p-value

1.317

<0.001

N/A
3.484
1.176
1.220
0.313
2.249

N/A
<0.001
<0.001
<0.001
0.03
<0.001

1.486
1.849

<0.001
<0.001

3.208
2.948
0.947

<0.001
<0.001
<0.001

1.163
3.801
N/A

<0.001
<0.001
N/A

Table 5
Heterogeneity in the male incidence rates of ARF
Stratification

I2
(%)
99

Overall
WHO Study Region
Americas
N/A
Western Pacific
99
South-East Asia
98
European
99
African
19
Eastern Mediterranean
99
Age 5
< Age 5
99
≥ Age 5
100
Decade
1990
100
2000s
99
Spans both
100
Diagnostic Criteria
1992 Jones Criteria
100
ICD 9/10
99
2012 Australian Guidelines
N/A
Note. I2 values of 100% were rounded.

τ2

p-value

2.1912

<0.001

N/A
4.296
1.669
1.382
0.021
3.139

N/A
<0.001
<0.001
<0.001
0.27
<0.001

1.852
3.817

<0.001
<0.001

3.983
3.310
1.975

<0.001
<0.001
<0.001

2.134
4.917
N/A

<0.001
<0.001
N/A
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When fixed effect models for male and female incidence were explored using metaregression, we observed that heterogeneity was not explained by any of the moderators (Table 6;
Table 7).
Table 6
Meta-regression in the Female Incidence Rates of Acute Rheumatic Fever
Stratification

QM

WHO Study Region
5.517
Americas
Western Pacific
South-East Asia
European
African
Eastern Mediterranean
Age 5
1.609
< Age 5
≥ Age 5
Decade
0.380
1990
2000s
Spans both
Diagnostic Criteria
2.275
1992 Jones Criteria
ICD 9/10
2012 Australian Guidelines
Note. I2 values of 100% were rounded.

Β

I2
(%)
99.09

-2.764
REF
-0.180
-0.793
-1.916
-1.241
99.18
-0.934
REF
99.32
REF
0.464
0.047
99.31
REF
1.229
-0.737
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p-value
0.356
0.074
REF
0.862
0.355
0.107
0.294
0.205
0.205
REF
0.827
REF
0.692
0.968
0.321
REF
0.173
0.614

Table 7
Meta-regression in the Male Incidence Rates of Acute Rheumatic Fever

Stratification

QM

WHO Study Region
7.085
Americas
Western Pacific
South-East Asia
European
African
Eastern Mediterranean
Age 5
1.472
< Age 5
≥ Age 5
Decade
0.4223
1990
2000s
Spans both
Diagnostic Criteria
1.963
1992 Jones Criteria
ICD 9/10
2012 Australian Guidelines
Note. I2 values of 100% were rounded.

β

I2
(%)
99.18

-3.087
REF
0.033
-0.775
-2.364
-1.061
99.35
-0.972
REF
99.51
REF
0.6750
0.268
99.52
REF
1.263
-0.691

p-value
0.214
0.056
REF
0.976
0.385
0.057
0.389
0.225
0.225
REF
0.810
REF
0.595
0.835
0.375
REF
0.200
0.666

Sensitivity analyses were also performed in which articles without exact population
denominators were excluded from analyses. Analyses revealed that heterogeneity did not differ
significantly between models, but did decrease slightly after the articles had been excluded. In
addition, there were no articles left in the African and Eastern Mediterranean countries after
exclusion. Meta-regression of the overall incidence rates showed negligible change in
significance levels for the moderators discussed previously. When stratified by gender, articles
that included children under the age of 5 were found to now introduce a significant amount of
heterogeneity in the models for both males and females (β = -1.515, p = 0.003; β = -1.368, p =
0.017, respectively). However, only 11 articles were used for this model, and all of them
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included children under the age of 5, indicating that no substantive change was made in the
significance levels of the moderators when accounting for how the population denominators
were calculated.
The proportion of studies that investigated the clinical and minor manifestations of ARF
can be found listed in Tables 7 & 8.
Table 7
Major Manifestations of Acute Rheumatic Fever

Article

Carditis
n (%)

Arthritis
n (%)

Chorea
n (%)

SN
n (%)

EM
n (%)

Noonan et al.
Smith et al.
Beaudoin et al.
Corsenac et al.
Steer et al.
Milne et al.
Atato-Carr et al.
Bavdekar
Ramu et al. (a)
Ramu et al. (b)
Routray
Zaman et al.
Ahmed et al.
Vinker et al.
Grassi et al.
Breda et al.
Kocevar et al.
Qurashi
Cilliers
Gapu et al.
Roodpeyma et al.
Karademir et al.
Karaaslan et al.
Narin et al.
Tunks et al.
Koo et al. (a)
Koo et al. (b)

90 (60)
21 (81)
47 (55)
36 (100)
36 (100)
1021 (77)
102 (76)
43 (49)
19 (100)
44 (53)
10 (63)
68 (67)
59 (26)
137 (50)
339 (54)
35 (59)
-

87 (58)
10 (38)
17 (20)
12 (33)
12 (33)
589 (44)
71 (53)
52 (59)
64 (77)
5 (31)
67 (66)
100 (44)
223 (81)
218 (35)
27 (46)
-

29 (19)
4 (15)
10 (12)
3 (8)
3 (8)
699 (53)
29 (21)
5 (6)
6 (32)
17 (20)
5 (31)
4 (4)
40 (18)
49 (18)
158 (25)
23 (39)
-

3 (2)
4 (5)
3 (8)
3 (8)
148 (11)
1 (1)
4 (5)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
2 (1)
3 (0.5)
0 (0)
-

8 (5)
0 (0)
0 (0)
0 (0)
0 (0)
8 (6)
10 (11)
1 (5)
0 (0)
0 (0)
1 (1)
0 (0)
1 (0.4)
1 (0.2)
3 (5)
-
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Table 8
Minor Manifestations of Acute Rheumatic Fever

Article

Fever
n (%)

Arthralgia
n (%)

Elevated
ESR
n (%)

Elevated
CRP
n (%)

Noonan et al.
Smith et al.
Beaudoin et al.
Corsenac et al.
Steer et al.
Milne et al.
Atato-Carr et al.
Bavdekar
Ramu et al. (a)
Ramu et al. (b)
Routray
Zaman et al.
Ahmed et al.
Vinker et al.
Grassi et al.
Breda et al.
Kocevar et al.
Qurashi
Cilliers
Gapu et al.
Roodpeyma et al.
Karademir et al.
Karaaslan et al.
Narin et al.
Tunks et al.
Koo et al. (a)
Koo et al. (b)

96 (64)
19 (73)
24 (67)
24 (67)
1170 (88)
68 (50)
70 (80)
15 (79)
69 (83)
11 (69)
113 (50)
109 (17)
-

36 (24)
7 (27)
5 (14)
5 (14)
22 (16)
42 (48)
12 (63)
9 (11)
6 (38)
164 (72)
211 (34)
-

19 (73)
80 (93)
17 (47)
17 (47)
14 (74)
74 (89)
8 (50)
102 (100)
223 (98)
225 (82)
376 (60)
-

11 (42)
58 (67)
31 (86)
31 (86)
11 (58)
7 (44)
182 (80)
280 (45)
-

Prolonged
PR
Interval
n (%)
8 (5)
7 (8)
2 (6)
2 (6)
2 (1)
5 (6)
5 (26)
19 (23)
2 (13)
44 (19)
66 (24)
108 (17)
-

However, because this information was extremely limited in how these were measured, it
was not appropriate to explore these further. Information on risk factors associated with ARF
was also not consistent between studies, so this data was unable to be pooled (data not shown).
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Chapter 5 Discussion
This meta-analysis provides evidence that heterogeneity exists as an issue when
exploring the global incidence rates of ARF. Significant heterogeneity was found between and
even within the WHO Study Regions and in articles that included children under the age of 5
years. The estimated average risk ratio was found to be significantly higher for the Americas and
the African countries compared to the Western Pacific. This confirms previous findings that the
incidence rates in the Western Pacific are typically the highest seen globally (Kumar & Tandon,
2013). In the case of WHO study region, heterogeneity could have been introduced in the study
methods or the populations within this region compared to other regions. On the other hand, the
estimated average risk ratio was significantly lower for studies that included children under the
age of 5 compared to those that did not. This suggests that heterogeneity could have been caused
by the way the studies were conducted or differences in case definitions used in each study. The
trend seen for the year of inclusion was also interesting since incidence rates to not appear to be
increasing. The increase in sensitivity of the diagnostic criteria for ARF from 1992 to 2015, this
may be showing an increased incidence due to decreased misdiagnosis of ARF. The substantial
amount of heterogeneity emphasizes the need for a more standardized approach when evaluating
and studying ARF. Without a cohesive method for assessing ARF cases, a true global estimate
cannot be determined.
The results also indicated that other variables need to be evaluated to determine the cause
of heterogeneity among male and female cases of ARF, since the variables in the present study
did not explain the source of the heterogeneity. However, a few trends were present among
males. Even though overall the WHO study region was not significant, the Western Pacific
Region and the Southeast Asia Region both had borderline significant p-values (0.057 and 0.077,
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respectively). This suggests that heterogeneity may be introduced by these specific regions, but
the same was not apparent for females. More than likely, there are some other characteristics of
these populations or differences between study methods that are introducing heterogeneity into
the current study. Future studies should explore possible explanations, such as percent
disadvantaged population studied, case definition for ARF and inclusion/exclusion criteria.
This study was unable to further explore the manifestations associated with ARF due to
limited availability of information provided by the authors. However, when comparing
proportions of major manifestations with recent reviews on the manifestations of ARF, some
interesting observations were made (Bono-Neri, 2017; Gewitz et al., 2015; Webb et al., 2015).
After pooling data from articles describing ARF, Webb et al. (2015) found that 50-65% of ARF
patients presented with carditis, globally. However, the articles included in the current metaanalysis revealed a range of 26-100% of patients presenting with carditis. In addition, Gewitz et
al. (2015) suggested that arthritis manifests in 50-70% of ARF patients, but the current analysis
showed a range of 31-81%. Lastly, previous research indicates that Sydenham’s Chorea
manifests in 10-30% of patients, differing slightly from the range of 4-39% found in the current
study. Subcutaneous nodules and erythema marginatum were the only two manifestations that
did not appear to diverge from what has been found in the literature (Bono-Neri, 2017; Gewitz et
al., 2015). These observations suggest that we do not fully understand the extent of how these
manifestations are distributed globally, especially the manifestations that are considered severe.
The limited availability further indicates the needs for a more systematic approach when
studying ARF.
Future research should explore the clinical manifestations, and explore the possibility that
differences may exist depending on geographical region, or possibly the strain of S. pyogenes. It
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is obvious with the results of the current meta-analysis that there is a large degree of uncertainty
in the description of the range of manifestations that are attributable to ARF. The results also
indicate that there may be a large underestimation in symptoms, such as carditis and arthritis.
The underestimation found in carditis could possibly reflect the issue of diagnosing subclinical
carditis in patients (Eroğlu, 2015; Gewitz et al., 2015). It is possible that studies using
echocardiogram technology instead of electrocardiography, they had the ability to diagnose more
cases of carditis (Eroğlu, 2015). The difference between the ranges found for arthritis could
possibly be due to similarities between the signs and symptoms of arthritis and arthralgia (Braun
et al., 1990). Patients may have not have understood the difference between these manifestations,
thus causing them to be misclassified. Unfortunately, no ranges were available on minor criteria,
such as arthralgia, so the answer to the discrepancy remains uncertain. Since these reviews did
not report ranges for any of the minor manifestations, it may be beneficial to explore the
possibility of differences also existing between groups for some of these symptoms.
The ability to accurately describe ARF reflects our ability to accurately diagnose ARF.
This is vital in ensuring that all individuals with this disease are properly evaluated and treated.
Underdiagnoses of ARF may lead to recurrent attacks, which increases the chance of cardiac
damage and premature death (The Australian Guidelines, 2015). Although the sensitivity of the
Jones Criteria has increased with each revision, there are still cases that are missed. One study
that investigated the impact of the addition of subclinical carditis, mono-arthritis, and low-grade
fever to the 1992 Jones Criteria found that, before the modification, only 71.4% of cases met the
criteria (Carapetis & Currie, 2001). With the modification, 91.8% of the cases satisfied the
criteria. Of those who did not meet the traditional criteria, 42% developed RHD, which means
that they had cases of ARF that went untreated (Carapetis & Currie, 2001). With further
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understanding of ARF in each population, interventions can be created and implemented that
better target each respective group.
Issues with the Jones Criteria
In areas where ARF is endemic, the definition of the “high-risk populations” category is
still not sensitive enough to capture all cases (Eroğlu, 2015). Research suggests that host genetic
susceptibility, virulence factors of Streptococcus pyogenes and environmental factors are all
individual and community level risk factors that may contribute to the development of ARF, but
they are not included in the definition for high-risk populations in the Jones Criteria (Baroux et
al., 2013; Steer et al., 2002). With the Jones Criteria only accounting for the incidence of the
population as the sole determinant of risk, this fails to consider any individual level predictors of
ARF that may put an individual at a higher risk of developing the disease. Including these
predictors could redefine levels of risk within the Jones Criteria to better diagnose ARF cases
that fall outside the current definition of high-risk populations.
Though SCC is now considered a major manifestation, individuals who have SCC are
still being missed during diagnosis. Carditis is the manifestation most often used in determining
disease status, which means atypical presentation of this manifestation can result in a
misdiagnosis (Eroğlu, 2015). SCC is a condition that can occur in ARF cases in which they
develop carditis due to the disease, but it is not able to be detected by an ECG during diagnosis.
This condition is better detected by echocardiography, which is included in the current diagnostic
criteria, but endemic regions often do not have access to this type of technology (Eroğlu, 2015;
Kumar & Tandon, 2013). Approximately 65% of individuals with ARF develop carditis as a
symptom, which means the other 35% could potentially have undetected SCC (Carapetis, Steer,
Mulholland & Weber, 2005; Kumar & Tandon, 2013).
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A systematic review that pooled data from studies looking at SCC in ARF cases
suggested that the weighted pooled prevalence of SCC among exposed individuals was 16.8%
(Tubridy-Clark & Carapetis, 2007). Another study found that clinically identifiable carditis was
present in 64% of cases, whereas SCC was diagnosed in 27% of cases resulting in an overall
prevalence of 91% (Veasy, 1999). When patients were followed up in a longitudinal study, initial
evaluation went from 56% having clinical carditis and 35% having SCC to 65% having clinical
carditis by the end of the follow-up time (Araújo, Goulart, & Meira, 2012). This not only
suggests that a large amount of cases of ARF go undiagnosed, but also that SCC can get worse
and turn into clinical carditis if not detected (Kumar & Tandon, 2013). Thus, the estimated
burden of this disease is an underestimate of the actual burden of the disease.
Due to geographical differences between cases of ARF, it is important that future
revisions of the Jones Criteria consider individual and genetic differences in addition to the
current groupings in the Guidelines when defining the level of risk associated with each group.
Individual characteristics that should be considered include SES, overcrowding status, and
rurality that may put certain individuals at an even higher risk of ARF. The more specific the
criteria are, less cases are missed in areas where the disease is endemic. In addition, once
biomarkers continue to be identified for ARF, adding these tests to the diagnostic criteria may
more accurately identify abnormal cases of ARF that may have been missed previously due to
incompatible symptoms. This would ensure that cases that do not have the typical symptoms,
such as in recurrent cases, are not missed.
Gaps in the Research
Information on the major and clinical manifestations and the risk factors associated with
ARF were not well documented in the literature. Most articles are concerned with the major

60

criteria, with even less reporting statistics on the minor, non-specific criteria. Even so, it is
evident that manifestations are not consistent across studies. The literature shows that carditis
and arthritis compete for the most frequent major manifestation, and chorea rates tend to have a
large range (6 to 36%). In one case, involuntary body movements was the most common
manifestation (Narin et al., 2013). The only consistency seems to appear in the instance of SN
and EM due to their infrequency across geographical location. However, one author
hypothesized that EM may be less apparent on darker skin, which means this symptom could be
underdiagnosed in regions of the world where the disease is epidemic (Steer et al., 2009). Further
exploring minor manifestations in addition to risk factors may help in identifying differences that
may exist between groups that have not been previously identified due to lack of available data.
Now that the Jones Criteria differentiates between initial and recurrent attacks, it would
be beneficial to understand what differences arise between these groups. Two recent papers have
explored the differences in manifestations between initial and recurrent attacks. Sheikh, Sadiq
and Rehman (2016) showed that arthritis, fever, and history of sore throat occurred more often in
initial episodes, while carditis, subcutaneous nodules, and arthralgia occurred more often in
recurrent episodes. Chorea and EM were found in neither recurrent nor initial attacks in this
sample. The results from Chagani and Aziz (2003) found similar results, with arthritis and
history of sore throat being more common in initial attacks, and carditis and arthralgia was more
common among recurrent attacks. However, they found that subcutaneous nodules were more
common among initial attacks and fever occurred more often during recurrent attacks. In
addition, their sample showed that both chorea and erythema marginatum was more common in
initial attacks. This research shows that not only do symptoms differ between initial and
recurrent attacks, but these manifestations also differ in frequency between populations. This
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provides evidence that definitions for initial and recurrent attacks that is currently used in the
Jones Criteria is not generalizable to all populations. However, there is not enough research
currently available that can accurately define these groups, which prompts the needs for
researchers to explore these differences. Another piece of evidence that may provide insight is
knowing the frequency of ARF attacks among patients, and not just if it is recurrent or initial.
Though with underreporting being so high with this disease, this may not be information that is
easily acquired. If this information can be obtained, a dose-response relationship may be able to
be identified. However, research has shown that damage accumulates over time with repeated
ARF attacks (Chang, 2012; Cunningham, 2000). With repeated infections means recurring
cardiac damage that can either target the same place or travel to other parts of the heart, often
ending in pancarditis (Eroğlu, 2015). This emphasizes the need to track and understand the
progression of this disease.
Only one study investigated the differences found between high and low risk group
classifications for ARF. Noonan et al. (2013) found that there were some differences between
manifestations that were apparent in each group. Aseptic monoarthritis was common among
children in the high-risk group (19%), but was only seen in one child in the low-risk group. The
authors also found that the proportion of raised inflammatory markers, chorea and cutaneous
manifestations were more common among the low risk group. Future research should explore the
differences between these groups among different populations to better describe what this
disease looks like for these groups. If differences are significant, major and minor classifications
may be revised to reflect which manifestations are more frequent for each group.
There are also limited current studies that explore the inheritance of ARF among family
members. Research indicates that heritability is still a factor in determining the development of
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ARF. Noonan et al. (2013) discovered that 9% of children with ARF had at least one sibling that
had a history of ARF. Similarly, Narin et al. (2015) found that 7.4% of Turkish patients had a
family history of ARF. A study in Italy showed 8% of their patients had a family history of ARF
(Breda et al., 2012). Globally, it appears that heritability remains consistent across populations.
Comprehensive studies on siblings and families would be beneficial to determine the
concordance of symptoms among family members that may help identify specific genes that may
be associated with the development of ARF.
Reducing the gaps in the research is the first step towards developing a more concreate
description of what this disease looks like today, on a global scale. Not only can a more sensitive
criterion be created once the holes in the data are filled, but individuals will have a better chance
of being identified and receive the treatment that they need.
Public Health Implications
The public health implications of this disease span across multiple aspects of prevention.
The proper diagnosis of sore throats is important in preventing the progression from pharyngitis
to ARF, in addition to providing antibiotics at this stage if clinical diagnosis is confirmed.
Surveillance of this disease needs to be established in endemic countries to help provide a better
system for following up with cases in addition to allowing for a more systematic way of
collecting data for analysis. Primary prevention with a suitable vaccine would be the most ideal
solution to prevent initial infection with S. pyogenes, since it would then reduce the number of
those who have both ARF and RHD. Since a vaccine is not yet feasible due to the variability of
this disease, public health interventions should focus on providing individuals clinically
diagnosed with pharyngitis with the antibiotic treatment they need. Awareness and education of
health care staff and patients is also needed to increase the amount of confirmed ARF cases
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receiving treatment. For those who do have ARF, proper management of this disease needs to be
emphasized so as to reduce potential damage that may occur if protocol is not followed and that
recurrence of ARF does not occur. These strategies should be employed in places where this
disease is endemic to increase the quality of life for these individuals and to reduce the burden of
ARF and RHD.
Diagnosing Sore Throats
In most developed and developing countries, the diagnosis of GAS pharyngitis is made
via a laboratory culture of a throat swab of the suspected patient (Kerdemelidis et al., 2010 et al.,
2010). These swabs are either plated on agar for growth in a lab or a rapid strep test is used. The
sensitivity of this test seems to vary across populations and studies, but do take into account that
some individuals have this bacterium as normal flora (Kaplan, Top, Dudding & Wannamaker,
1971). If a rapid strep test comes back negative, it is recommended that a throat swab be done to
confirm those results (Bisno et al., 2002). In places like New Zealand where ARF is endemic,
however, the sensitivity of this test has not been validated (Kerdemelidis et al., 2010). Why this
is so important, is because the individuals in New Zealand have a high likelihood of testing
positive for GAS pharyngitis, which could result in the overuse of antibiotics. To combat this,
Kerdemelidis et al. (2010) proposed an algorithm that accounts for other risk factors (high pretest
probability of GAS infection) to properly prescribe the right patient with antibiotics. However,
the sensitivity needs to be assessed in different populations to determine the correct method to
prescribe medications.
Surveillance of ARF
In places where ARF is endemic, such as in New Zealand and Australia, there are
surveillance systems in place to track the disease. Other developed countries where ARF is still
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prevalent do not have these types of systems in place. In addition, developed countries no longer
closely track ARF cases except for hospital records. This is evident in the fact that in 1995, ARF
was taken off the notifiable disease list in the United States since the incidence rate had dropped
so low (CDC, 1995). Other places where this disease is endemic may also not have any
surveillance system at all. To better coordinate care, reduce recurrent ARF, and increase the
number of individuals who follow up for proper health care, registries must exist in countries
where ARF incidence is high.
Prevention Strategies
Primary and secondary prevention have both been employed as strategies to prevent or
treat ARF. It is critical that individuals with ARF receive adequate treatment and preventative
care to reduce the morbidity associated with this disease. Vaccines to protect against infection
with GAS has also been evaluated as the next step towards primary prevention of ARF
(Cunningham, 2000). Failure to provide secondary prophylaxis can be due to a missed diagnosis,
lack of continuity of professional care, lack of trust between patients and physicians, high staff
turnover, lack of appropriate health education on ARF, and lack of a political or bureaucratic
commitment to see that this problem is fixed (Brown, McDonald & Calma, 2007). In order for
these methods to be efficient, the underlying social determinants associated with ARF must first
be determined and alleviated.
Awareness and Education
It has been shown that not only do families not understand the risk of ARF, but hospital
staff in endemic areas often do not have adequate education on ARF prevention and treatment
(Zühlke et al., 2017). Hospital staff should be adequately trained in identifying the signs and
symptoms of this disease in places where it is endemic. Another method of increasing education
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is for hospitals to provide staff with materials that educate them on the signs and symptoms
associated with GAS and the importance of getting treated. Then, the staff can pass this
information on to the parent which, in-turn, will hopefully increase the chance of continuity of
care. Public Service Announcements (PSAs) in the form of infographics have been used recently
to try and bring awareness to this disease in places like New Zealand. However, it cannot be
determined if those living in remote regions have access to this information. Increasing the use of
PSAs in developing countries should increase the likelihood that someone seeks treatment for
sore throats, thus decreasing the incidence of ARF. If these individuals go in for treatment, they
should further be educated by hospital staff, and can take home information on ARF.
Primary Prevention
Currently, primary prevention of ARF is the treatment of a GAS infection with antibiotics
(Kumar & Tandon, 2013). This prevents the progression of strep throat to ARF from occurring in
the first place, and is the second-best form of primary prevention besides the creation of a
vaccine for S. pyogenes. However, limited access to adequate medical care makes it less likely
that individuals who are affected by ARF are receiving treatment at this stage. So, in the instance
of pharyngitis cases that turn into ARF, antibiotics are also used to treat the patient with ARF if
they still test positive for an infection with S. pyogenes to prevent recurrent infections from
occurring (Commerford, 2006).
GAS have remained sensitive to penicillin, but little has been done to reduce the number
of those who are affected by ARF in socially disadvantaged populations (Kumar & Tandon,
2013). In the United States, generic antibiotic prescriptions are available for either very reduced
prices or free of charge to those that have a valid prescription for it provided by a doctor
(National Conference of State Legislature [NCSL], 2012). Employing a similar program in
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developing countries could potentially help reduce the rates of ARF by ensuring access to
antibiotics when children are clinically shown to have developed pharyngitis due to S. pyogenes.
This may not completely alleviate the problem, especially in populations that live in remote areas
and may not have transportation to pick up antibiotics. In this case, it may be beneficial to
employ mobile units to these areas to distribute antibiotics to those who need them. However,
some research suggests that antibiotics may not completely prevent outbreaks from occurring,
but since S. pyogenes can still be treated with penicillin, resistance is not thought to be the main
culprit.
In developed countries where treatment with antibiotics is expected after a GAS
infection, unexplained resurgences of these infections have been observed since the mid-1980s
(Kaplan, 1991). Between the mid-1980s to the 1990s, there were eight ARF outbreaks
documented in the United States, all of them of increased severity compared to previous decades
(Ayoub, 1992; Bisno, 1993; Kaplan, 1991; Veasy, Wiedmeir & Orsmon, 1987). These strains
also deviated from past outbreaks in that middle-class families were at a higher risk of
contracting ARF compared to lower income families that were more commonly affected by ARF
previously (Bisno, 1993). If these patterns persist, the definition of high and low risk populations
will need to be shifted to appropriately diagnose future patients that may fall outside previous
definitions or expectations of this disease.
Previous vaccine strategies have been targeted towards specific M proteins, specifically
the type specific N-terminal region or the conserved C-terminal region (Bessen & Fischetti,
1997). Vaccines that target the N-terminal region, or the start of a polypeptide that has a free
anime group, induced protective bactericidal and opsonic antibody against the serotype (Beachey
et al., 1981; Beachey et al., 1986). This ultimately leads to phagocytosis of the organism (Chang,
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2012). Unfortunately, these antibodies are generally type specific, and since there are 80 M
subtypes, multiple coverage type vaccines seem unlikely (McNeil et al., 2005). An alternative
strategy is a vaccine that targets the C-terminal region, or the region of a polypeptide that has a
free carboxyl group, which were able to protect against multiple serotypes and prevented
colonization at mucosal surfaces (Dale, 1999; Dale, Chiang & Chiang, 1993). This broadened
the coverage of M proteins, but this highly conserved region possesses molecules that cross-react
with tropomyosin and myosin (Chang, 2012). Another vaccine is in development in Australia
that targets the B cell epitope on the conserved region of the M protein called J8 (Padney,
Batzloff & Good, 2009). They created a conjugate vaccine with the diphtheria toxoid (DT) and
an adjuvant that did produce immunity in mice, but the protection was not long lasting.
Even though these vaccines seem promising, there are still problems that must be
overcome. The bacterial antigens that cause cross-reactivity within host tissue is not
recommended to be used for making vaccines since host tissue could cause an adverse reaction
(Cunningham, 2000). To make a vaccine with effective protection, a combination of M protein
serotypes from rheumatogenic strains would have to be required, and now that 16 have been
identified to be associated with ARF, it makes it seem unlikely that one vaccine will suffice
(Cunningham, 2000). However, common GAS antigens that are not M proteins are currently
under investigation for their effectiveness of protecting against colonization of the bacteria
(Cunningham, 2000).
Management of ARF
Controlling inflammation to manage carditis, providing symptomatic relief and
eradicating pharyngeal streptococcal infection are techniques used to manage the symptoms of
ARF (Commerford, 2006; Zühlke et al., 2017). Suppressing the inflammatory response directly
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minimizes cardiac damage, providing symptom relief (Commerford, 2006). Aspirin has been the
primary anti-inflammatory used when there is no longer any evidence of an infection via a rapid
strep test, but research has shown that Naproxen may have equivalent efficacy with fewer side
effects (Hashkes et al., 2003). Anti-inflammatory agents are normally used in high dose for the
first two weeks of infection, and then decreased by 20% each week, depending on clinical
response and acute phase reactant levels (Commerford, 2006). Individuals with severe carditis
are treated with heart failure therapy along with bedrest (Zühlke et al., 2017). This is usually a
long-standing recommendation (Commerford, 2006). The duration is individually dependent,
with ambulation starting once the fever has dissipated and the acute phase reactants return to
normal. A 10-day course of penicillin is also recommended to prevent reinfection with GAS only
if the individual tests positive on a rapid strep test (Commerford, 2006). This is important so that
antibiotic resistance does not occur due to indiscriminate use of antibiotics. In some cases, heart
transplants are necessary when cardiac damage is too severe (Chang, 2012).
The economic burden of this disease is substantial, and encompass both direct and
indirect costs to the families of those affected. It is estimated that the individual cost of having a
GAS infection in the United States is between $250 and $400 million, indicating that the global
cost is much greater (Chang, 2012). Ongoing treatment with antibiotics, which can occur
multiple times if repeated infections occur, cardiac surgery, and hospitalization contribute to the
financial burden of this disease. If neurological symptoms, such as the involuntary body
movements of the hands, feet and face caused by Sydenham’s chorea, manifest in the child, the
financial burden is greatly increased (Chang, 2012). Some indirect costs are travel to the hospital
or primary care physician’s office, which is a great cost for those living in rural or remote areas,
loss of education of the child who is on bedrest, and caregivers lose income due to staying at
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home to care for the child. If children are treated for their initial sore throat, then the cost of this
disease can be greatly reduced. Penicillin, aspirin, and naproxen are all generic and relatively
inexpensive drugs. The creation of an effective vaccine would ultimately reduce the price in
addition to helping to eradicate the disease.
Strengths
To the author’s knowledge, there has been no other meta-analysis conducted on the
global incidence of ARF. Though the results were unable to be pooled due to heterogeneity, the
utilization of a meta-analysis did increase the power of analyses via larger sample sizes. As this
was a global perspective, greater generalizability was achieved. Finding the heterogeneity among
these studies also helped to identify the current gaps in the research and provides guidelines in
determining what future research should explore regarding ARF.
Limitations
Due to the nature of this study, there are a few limitations. First, the inclusion criteria for
the age range excluded possible cases that may occur at ages older than 19 (Chockalingam, A.,
Gnanavelu, Elangovan & Chockalingam, V., 2003; Miyake et al., 2007). Research shows that the
majority of ARF cases have an age of onset between 5 and 14 years of age, with papers reporting
87 to 95% of their populations falling within that age range (Narin et al., 2015; Noonan et al.,
2013; Vinker et al., 2010). When looking at ages older than 19, one study showed that only 4
(9.1%) cases were between 20 and 29 (Vinker et al., 2010). Another study found that 7 (6.6%)
ARF cases were in individuals over the age of 19 (Pennock et al., 2014). With the incidence rates
being higher among these groups, it was important that the scope of the analyses conducted for
this paper be focused on childhood ARF cases. This is evident in that the 2015 Australian
Guidelines lists the high-risk group as those aged between 5 and 14 with an incidence greater
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than 30 per 100,000 (Eroğlu, 2016). Understanding this disease during earlier age groups has
better public health implications with the possibility of earlier implementation of interventions.
Another limitation that arose was that multiple papers did not provide information
pertaining to population denominators used to calculate incidence rates. To combat this issue,
population denominators were pulled from government censuses, and when incidence rates were
calculated via this method, results were similar to what was reported in the corresponding papers.
In some cases, the exact population groups could not be matched to the age range that was used
in the study. For example, if the study looked at 0 to 15, but the government website only had
number for 0 to 14 and 15 to 24. In these cases, it was assumed that there was an equal number
of individuals at each age in the age group. To continue with the example above, the population
denominator from the government website was divided by the number of age groups (15), and
then that number was added to the total population to account for the missing value for 15-year
old individuals. However, sensitivity analyses were conducted in which articles without exact
population denominators were excluded from analyses, and these results indicated that
significance levels of the moderators did not change when these articles were excluded.
Since risk of bias for all included studies was only reviewed by a single reviewer, there is
a potential for reviewer bias to be introduced. Any issues with scoring that occurred during
review were adjudicated with the co-authors. However, since the studies were comprised mainly
of cross-sectional and cohort studies that strictly gave clinical profiles of ARF and did not run
comparisons, it was deemed unnecessary to have more than one reviewer assess the risk of bias.
In addition, research evaluating the assessment of the NOS scale between authors of studies and
reviewers of studies showed that the overall NOS score was significantly higher in the reviewer’s
assessment compared to those by the authors of their respective articles (median = 6 vs. 5, IQR
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6-6 vs. 4-6, p <0.001) (Lo, Mertz & Loeb, 2014). The authors argued that the one-point
difference found between these groups would likely not have any practical implications.
Another limitation for this paper was including the multiple types of diagnostic criteria
used to define a case of ARF. This could introduce misclassification bias due to differences in
sensitivity between the criteria. However, diagnostic criteria did not introduce a significant
amount of heterogeneity into the overall incidence rates. In addition, not all diagnostic criteria
mentioned in the inclusion criteria were evident in this study. Specifically, no articles used the
2015 Australian Guidelines for their case definitions of ARF. This may be because of how recent
the criteria were created, which means there is a lack of recent publications utilizing this case
definition. Future research utilizing the new diagnostic criteria may alleviate some of the issues
the current study discovered in the literature.
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Chapter 6 Conclusion
Although substantial heterogeneity existed between the pooled data for this study, the
results provide evidence of where gaps exist in the research regarding ARF on a global scale.
Properly describing the characteristics of this disease is the first step towards creating adequate
criteria and guidelines that will hopefully lead to better health outcomes for those suffering from
ARF, reduce the economic burden that this disease imposes on susceptible families, and
ultimately improve the quality of life of these individuals. ARF is a disease that is preventable
with the use of antibiotics, calling into question why this disease is still running rampant
globally. As advocates of health equity for all, it is important to remember that this not only
means equity on a national level, but also on a global level.
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Appendix 1

Figure A1. Overall Incidence Rates of Acute Rheumatic Fever in included studies stratified by
inclusion of those under or over the age of 5.
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Figure A2. Overall Incidence Rates of Acute Rheumatic Fever in included studies stratified by
the diagnostic criteria used.

75

Figure A3. Overall Incidence Rates of Acute Rheumatic Fever in included studies stratified by
the decade they were evaluated.
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Appendix 2

Figure A4. Female Incidence Rates of Acute Rheumatic Fever in included studies stratified by
WHO study region.
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Figure A5. Female Incidence Rates of Acute Rheumatic Fever in included studies stratified by
inclusion of children over or under the age of 5.
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Figure A6. Female Incidence Rates of Acute Rheumatic Fever in included studies stratified by
the decade they were evaluated.
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Figure A7. Female Incidence Rates of Acute Rheumatic Fever in included studies stratified by
the diagnostic criteria used.
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Figure A8. Male Incidence Rates of Acute Rheumatic Fever in included studies stratified by
WHO Study Region.
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Figure A9. Male Incidence Rates of Acute Rheumatic Fever in included studies stratified by
inclusion of children under or over the age of 5.
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Figure A10. Male Incidence Rates of Acute Rheumatic Fever in included studies stratified by
diagnostic criteria used.
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